Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non Small Cell Lung Cancer
Interventions
Paclitaxel, NOV-002, Carboplatin
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
12
States / cities
Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more
Conditions
Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
Interventions
L-alanosine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • La Verne, California + 7 more
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma, Breast Adenocarcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection, Biopsy, Computed Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
16 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Lung Cancer
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Miami, Florida + 6 more
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration
Other · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 11 more
Conditions
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, Plinabulin, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
101
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
Interventions
radiofrequency ablation
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions
Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Survey Administration, Volume Modulated Arc Therapy, Hippocampal-Avoidance Craniospinal Irradiation
Procedure · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Conditions
Non-Small Cell Lung Cancer
Interventions
Cetuximab, Bevacizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
43
States / cities
Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 39 more
Conditions
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Immune Checkpoint Inhibitor
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Erlotinib, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
70 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tampa, Florida